London, UK (PRWEB) February 03, 2015
Over the next few years, the stem cells market is poised to continue to be the most rapidly growing segment, which includes the segments for concentrated bone marrow and stem cell bone grafts. Stem cells provide greater osteogenesis and osteoinductive properties than other bone grafts, and thus enhance bone repair. To date, their usage is only considered for the treatment of spine cord injuries, but the market is likely to witness further expansion in case other indications are approved, such as with the foot where a number of patients may experience poor vascularisation.
The orthopedic biomaterials market in the USA is forecast to gain traction through 2021. The ageing population is a key factor driving the market. In tandem with the surging ageing population, the incidence rates of osteoarthritis and other types of degenerative disorders are also expected to grow, thus driving the demand for orthopedic biomaterials. Additionally, a huge portion of the overall biomaterial products market is engaged in treating soft tissue injuries, and most of them are sport-related. However, high costs of the development of some products could hinder the sector’s growth. Furthermore, the timeliness of a product’s final approval is often hard to foretell.
Medtronic dominated the orthopedic biomaterials market as of 2014, due to the lion’s share of the bone graft substitute sector. The company announced in June 2014 its intention to buy Covidien for USD 42.9 billion.
In-demand study “U.S. Orthopedic Biomaterials Market” worked out by iData Research has been recently published at MarketPublishers.com.
Title: U.S. Orthopedic Biomaterials Market
Published: January, 2015
Price: US$ 6,995.00
The research report contains an all-encompassing analysis and forecast of the orthopedic biomaterials market across the USA up to 2021. It provides detailed market analyses of leading market segments, including bone graft substitutes, hyaluronic acid viscosupplementation, orthopedic stem cells, growth factors, cartilage repair, cell therapy, and machined bone allografts; the categories are further subdivided into subcategories by various parameters. The study identifies the game-changing opportunities and potential hazards in the market, traces the key trends and technologies expected to impact the overall market and each of its individual segments in the years to come, as well as sheds light on the market drivers and restraints. Essential information on the number of procedures is provided. Furthermore, the research study canvasses the competitive landscape as well as discusses the top 22 companies along with their success strategies, M&As, etc.
- All-round picture of the orthopedic biomaterial products market in the United States.
- Granular market analysis by leading segments and subsegments.
- Information on the procedure volumes.
- Identification of the major strategic opportunities.
- Insightful analysis of the key trends in the total market and across each segment.
- In-depth review of the major factors stimulating and limiting the growth in the sector.
- Detailed analysis of the competitive scene including vital information on the dominant market players.
- Overview of the recent M&A activity landscape.
- The US orthopedic biomaterials market’s development path through 2021.
- Customer feedback and market monitoring.
More in-demand reports by the publisher can be found at iData Research page.